Research ArticleCancer

Metabolomic Imaging for Human Prostate Cancer Detection

See allHide authors and affiliations

Science Translational Medicine  27 Jan 2010:
Vol. 2, Issue 16, pp. 16ra8
DOI: 10.1126/scitranslmed.3000513

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


As current radiological approaches cannot accurately localize prostate cancer in vivo, biopsies are conducted at random within prostates for patients at risk for prostate cancer, leading to high false-negative rates. Metabolomic imaging can map cancer-specific biomolecular profile values onto anatomical structures to direct biopsy. In this preliminary study, we evaluated five whole prostates removed during prostatectomy from biopsy-proven cancer patients on a 7-tesla human whole-body magnetic resonance scanner. Localized, multi–cross-sectional, multivoxel magnetic resonance spectra were used to construct a malignancy index based on prostate cancer metabolomic profiles obtained from previous intact tissue analyses with a 14-tesla spectrometer. This calculated malignancy index is linearly correlated with lesion size and demonstrates a 93 to 97% overall accuracy for detecting the presence of prostate cancer lesions, suggesting the potential clinical utility of this approach.


  • * These authors contributed equally to this work.

  • Citation: C.-L. Wu, K. W. Jordan, E. M. Ratai, J. Sheng, C. B. Adkins, E. M. DeFeo, B. G. Jenkins, L. Ying, W. S. McDougal, L. L. Cheng, Metabolomic Imaging for Human Prostate Cancer Detection. Sci. Transl. Med. 2, 16ra8 (2010).

View Full Text

Stay Connected to Science Translational Medicine